Insider Selling: Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Major Shareholder Sells $39,015,179.28 in Stock

by · The Markets Daily

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA – Get Free Report) major shareholder Orbimed Advisors Llc sold 860,123 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $45.36, for a total transaction of $39,015,179.28. Following the completion of the transaction, the insider owned 219,405 shares of the company’s stock, valued at $9,952,210.80. This trade represents a 79.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Monday, June 15th, Orbimed Advisors Llc sold 281,408 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $45.02, for a total value of $12,668,988.16.

Bitwise MARA Option Income Strategy ETF Stock Up 2.0%

NYSEARCA IMRA opened at $17.43 on Friday. The stock’s 50-day simple moving average is $16.79 and its two-hundred day simple moving average is $15.74. Bitwise MARA Option Income Strategy ETF has a twelve month low of $11.99 and a twelve month high of $54.94. The company has a market capitalization of $3.31 million, a price-to-earnings ratio of 348.60 and a beta of 2.88.

About Bitwise MARA Option Income Strategy ETF

(Get Free Report)

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.

Featured Stories